Cargando…

PB2151: CLINICAL FEATURES AND OUTCOMES OF DIFFUSE PULMONARY LIGHT CHAIN AMYLOIDOSIS: A RARE PRESENTATION OF SYSTEMIC AL AMYLOIDOSIS

Detalles Bibliográficos
Autores principales:	Chakraborty, Rajshekhar, Bellofiore, Claudia, Basset, Marco, Nuvolone, Mario, Foli, Andrea, Merlini, Giampaolo, Palladini, Giovanni, Maurer, Mathew, Mapara, Markus, Bhutani, Divaya, Lentzsch, Suzanne, Milani, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429335/ http://dx.doi.org/10.1097/01.HS9.0000975364.74026.0a

Ejemplares similares

Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis
por: Chakraborty, Rajshekhar, et al.
Publicado: (2023)

The lung in amyloidosis
por: Milani, Paolo, et al.
Publicado: (2017)

Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy
por: Milani, Paolo, et al.
Publicado: (2020)

Light Chain Amyloidosis
por: Milani, Paolo, et al.
Publicado: (2018)

Novel Therapies in Light Chain Amyloidosis
por: Milani, Paolo, et al.
Publicado: (2017)

Sars-Cov-2 Infection and Systemic Light Chain Amyloidosis: The International Society of Amyloidosis' Survey
por: Milani, Paolo, et al.
Publicado: (2020)

Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis
por: Palladini, Giovanni, et al.
Publicado: (2021)

Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis
por: Nuvolone, Mario, et al.
Publicado: (2022)

A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis
por: Sidana, Surbhi, et al.
Publicado: (2020)

PB1989: LIGHT CHAIN AMYLOIDOSIS (AL): THE EXPERIENCE OF A TUNISIAN CENTER
por: Kallel, F., et al.
Publicado: (2022)

Editorial: Advances in the understanding of pathogenesis, diagnosis, and therapy of light chain amyloidosis
por: Bhutani, Divaya, et al.
Publicado: (2023)

Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis: insights into the timing of proteolysis
por: Lavatelli, Francesca, et al.
Publicado: (2021)

PB2008: CUTANEOUS HEMORRHAGIC SYNDROME IN PATIENTS WITH AL-AMYLOIDOSIS
por: Khyshova, V., et al.
Publicado: (2022)

PB2151: EVALUATION OF BONE MINERAL DENSITY IN LYMPHOMA PATIENTS WITH USING PET/CT AND THE ROLE OF BCL-2
por: Okan, V., et al.
Publicado: (2022)

AL AMYLOIDOSIS: MECHANISMS OF DISEASE AND BIOMARKERS
por: Palladini, Giovanni, et al.
Publicado: (2022)

PB2155: B-CELL NON-HODGKIN’S LYMPHOMAS ASSOCIATED WITH AMYLOIDOSIS
por: Navrátilova, M., et al.
Publicado: (2022)

PB2135: TREATMENT PATTERNS IN PATIENTS WITH NEWLY DIAGNOSED AL AMYLOIDOSIS
por: D’souza, Anita, et al.
Publicado: (2023)

Protease‐sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation
por: Mazzini, Giulia, et al.
Publicado: (2021)

Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis
por: Palladini, Giovanni, et al.
Publicado: (2021)

Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium
por: Lousada, Isabelle, et al.
Publicado: (2015)

Dual targeting of protein translation and nuclear protein export results in enhanced antimyeloma effects
por: Li, Shirong, et al.
Publicado: (2023)

PB2154: THE IMPACT OF DISEASE SEVERITY ON THE CLINICAL AND ECONOMIC BURDEN OF AL AMYLOIDOSIS
por: D’souza, Anita, et al.
Publicado: (2023)

Proposed Cardiac End Points for Clinical Trials in Immunoglobulin Light Chain Amyloidosis: Report From the Amyloidosis Forum Cardiac Working Group
por: Maurer, Mathew S., et al.
Publicado: (2022)

PB1988: AL CARDIAC AMYLOIDOSIS: A CASE SERIES OF 13 PATIENTS AND LITERATURE REVIEW
por: Chadli, S., et al.
Publicado: (2022)

PB2025: MANAGEMENT AND PATIENT ESTIMATION OF AMYLOID LIGHT-CHAIN (AL) AMYLOIDOSIS IN PORTUGAL: RESULTS FROM A PHYSICIANS’ SURVEY
por: Santos, S., et al.
Publicado: (2022)

PB2319: ACQUIRED COAGULOPATHY: FACTOR X DEFICIENCY AT DIAGNOSIS OF MULTIPLE MYELOMA WITHOUT ASSOCIATED AMYLOIDOSIS
por: De La Torre De La Paz, M., et al.
Publicado: (2022)

P823: BONE MARROW-FREE SEQUENCING OF M PROTEIN GENES IN MONOCLONAL GAMMOPATHIES
por: Nevone, Alice, et al.
Publicado: (2023)

PB2102: IMPACT OF AUTOLOGOUS STEM CELL TRASPLANTATION IN AL AMYLOIDOSIS. EXPERIENCE IN A SINGLE TERTIARY HOSPITAL
por: Alonso, Elena Alejo, et al.
Publicado: (2023)

DUAL expectations in light chain amyloidosis
por: Schönland, Stefan, et al.
Publicado: (2020)

PB2150: CARDIAC AMYLOID REACHING FOR EXTENDED SURVIVAL (CARES) TRIALS: 2 PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED, PHASE 3 TRIALS ASSESSING CAEL-101 IN PATIENTS WITH MAYO STAGES IIIA/IIIB AL AMYLOIDOSIS
por: Wechalekar, Ashutosh, et al.
Publicado: (2023)

Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient
por: Swuec, Paolo, et al.
Publicado: (2019)

Cryo-EM structure of ex vivo fibrils associated with extreme AA amyloidosis prevalence in a cat shelter
por: Schulte, Tim, et al.
Publicado: (2022)

Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells
por: Imperlini, Esther, et al.
Publicado: (2017)

PB2161: BORTEZOMIB, POMALIDOMIDE, AND DEXAMETHASONE IS AN EFFECTIVE REGIMEN FOR PATIENTS WITH RELAPSE AND REFRACTORY AL AMYLOIDOSIS AND MONOCLONAL IMMUNOGLOBULIN DEPOSITION DISEASE
por: Liu, Yang, et al.
Publicado: (2023)

Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis
por: Premkumar, Vikram J., et al.
Publicado: (2021)

In situ characterization of protein aggregates in human tissues affected by light chain amyloidosis: a FTIR microspectroscopy study
por: Ami, Diletta, et al.
Publicado: (2016)

Phase I/II study of carfilzomib, bendamustine, and dexamethasone (CBD) in patients with newly diagnosed multiple myeloma
por: Leng, Siyang, et al.
Publicado: (2020)

Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis
por: Aimo, Alberto, et al.
Publicado: (2021)

PB2030: CLINICAL, LABORATORY PROFILE, TREATMENT AND OUTCOME OF PRIMARY AMYLOIDOSIS IN THE ERA OF NOVEL AGENTS: AN EXPERIENCE FROM A TERTIARY CARE HOSPITAL IN INDIA
por: Sivaprakasam, Y., et al.
Publicado: (2022)

PB2097: CLINICAL IMPLICATION OF CYTOGENETIC ABERRATIONS IN NON-AL AMYLOIDOSIS MONOCLONAL GAMMOPATHY OF RENAL SIGNIFICANCE: A MULTI-CENTER CHINESE CASE SERIES
por: Liu, Yang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6ci55kb6vg6kveg9gamijfcvg4